XML 25 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue
12 Months Ended
Dec. 31, 2021
Revenue.  
Revenue

6. Revenue

The Company recognized revenue under its license and collaboration agreement with SymBio as follows (See Note 14):

Year ended December 31, 

    

2021

    

2020

Symbio

Upfront license fee recognition over time

$

226,000

$

226,000

Supplies

5,000

$

226,000

$

231,000

Deferred revenue is as follows:

Symbio

    

Upfront Payment

Deferred balance at December 31, 2020

$

3,695,000

Recognition to revenue

226,000

Deferred balance at December 31, 2021

$

3,469,000